Corcept Therapeutics (CORT) Q4 2024 earnings summary

Executive summary

• 2024 revenue reached $675 million, up 40% year-over-year, with net income of $141.2 million, a 33% increase.

• Record growth in new Korlym prescribers and patients, driven by increased awareness and screening for hypercortisolism; strong growth in Cushing's syndrome business expected to continue.

• NDA for relacorilant submitted December 2024, supported by strong clinical data from GRACE, GRADIENT, and phase II studies.

• Ongoing pivotal studies in oncology (ROSELLA, prostate cancer), ALS, and MASH.

• Significant clinical progress in relacorilant and other pipeline programs.

Financial highlights

• Q4 2024 revenue was $181.9 million, up from $135.4 million in Q4 2023.

• Cash and investments at year-end totaled $603.2 million, up from $425.4 million the previous year.

• $38 million spent on stock repurchases and equity compensation in 2024.

• Full-year net income was $141.2 million ($1.23 diluted EPS), compared to $106.1 million ($0.94 diluted EPS) in 2023.

• Operating expenses for 2024 were $538.1 million, up from $375.1 million in 2023.

Outlook and guidance

• 2025 revenue guidance set at $900–$950 million, reflecting continued growth expectations.

• Market for hypercortisolism is expanding rapidly, with long-term annual revenue potential projected at $3–$5 billion in 3–5 years.

• Continued growth anticipated in Cushing's syndrome business and expansion into new indications.

• Pharmacy operational issues are being resolved, supporting future growth.